➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Merck
Harvard Business School
Medtronic
Johnson and Johnson

Last Updated: March 7, 2021

DrugPatentWatch Database Preview

SULAR Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Sular patents expire, and what generic alternatives are available?

Sular is a drug marketed by Covis and is included in one NDA.

The generic ingredient in SULAR is nisoldipine. There are eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the nisoldipine profile page.

US ANDA Litigation and Generic Entry Outlook for Sular

A generic version of SULAR was approved as nisoldipine by MYLAN on July 25th, 2008.

  Start Trial

Summary for SULAR
Drug patent expirations by year for SULAR
Drug Prices for SULAR

See drug prices for SULAR

Pharmacology for SULAR
Paragraph IV (Patent) Challenges for SULAR
Tradename Dosage Ingredient NDA Submissiondate
SULAR TABLET, EXTENDED RELEASE;ORAL nisoldipine 020356 2009-03-02
SULAR TABLET, EXTENDED RELEASE;ORAL nisoldipine 020356 2008-11-28
SULAR TABLET, EXTENDED RELEASE;ORAL nisoldipine 020356 2007-11-07
SULAR TABLET, EXTENDED RELEASE;ORAL nisoldipine 020356 2007-06-11

US Patents and Regulatory Information for SULAR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Covis SULAR nisoldipine TABLET, EXTENDED RELEASE;ORAL 020356-008 Jan 2, 2008 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Covis SULAR nisoldipine TABLET, EXTENDED RELEASE;ORAL 020356-005 Jan 2, 2008 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Covis SULAR nisoldipine TABLET, EXTENDED RELEASE;ORAL 020356-002 Feb 2, 1995 DISCN Yes No   Start Trial   Start Trial   Start Trial
Covis SULAR nisoldipine TABLET, EXTENDED RELEASE;ORAL 020356-004 Feb 2, 1995 DISCN Yes No   Start Trial   Start Trial   Start Trial
Covis SULAR nisoldipine TABLET, EXTENDED RELEASE;ORAL 020356-001 Feb 2, 1995 DISCN Yes No   Start Trial   Start Trial   Start Trial
Covis SULAR nisoldipine TABLET, EXTENDED RELEASE;ORAL 020356-007 Jan 2, 2008 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for SULAR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Covis SULAR nisoldipine TABLET, EXTENDED RELEASE;ORAL 020356-004 Feb 2, 1995   Start Trial   Start Trial
Covis SULAR nisoldipine TABLET, EXTENDED RELEASE;ORAL 020356-002 Feb 2, 1995   Start Trial   Start Trial
Covis SULAR nisoldipine TABLET, EXTENDED RELEASE;ORAL 020356-008 Jan 2, 2008   Start Trial   Start Trial
Covis SULAR nisoldipine TABLET, EXTENDED RELEASE;ORAL 020356-001 Feb 2, 1995   Start Trial   Start Trial
Covis SULAR nisoldipine TABLET, EXTENDED RELEASE;ORAL 020356-005 Jan 2, 2008   Start Trial   Start Trial
Covis SULAR nisoldipine TABLET, EXTENDED RELEASE;ORAL 020356-004 Feb 2, 1995   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Boehringer Ingelheim
Medtronic
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.